KR101371653B1 - 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도 - Google Patents

약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도 Download PDF

Info

Publication number
KR101371653B1
KR101371653B1 KR1020067024974A KR20067024974A KR101371653B1 KR 101371653 B1 KR101371653 B1 KR 101371653B1 KR 1020067024974 A KR1020067024974 A KR 1020067024974A KR 20067024974 A KR20067024974 A KR 20067024974A KR 101371653 B1 KR101371653 B1 KR 101371653B1
Authority
KR
South Korea
Prior art keywords
delete delete
drug
compound
phenyl
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067024974A
Other languages
English (en)
Korean (ko)
Other versions
KR20070017393A (ko
Inventor
코엔라아드 조제프 로데위지크 마르셀 안드리에스
게스텔 조제프 프란스 엘리자베싸 반
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101371653(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20070017393A publication Critical patent/KR20070017393A/ko
Application granted granted Critical
Publication of KR101371653B1 publication Critical patent/KR101371653B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067024974A 2004-05-28 2005-05-24 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도 Expired - Lifetime KR101371653B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04102402 2004-05-28
EP04102402.7 2004-05-28
PCT/EP2005/052371 WO2005117875A1 (en) 2004-05-28 2005-05-24 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137002606A Division KR20130024969A (ko) 2004-05-28 2005-05-24 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린 유도체의 용도

Publications (2)

Publication Number Publication Date
KR20070017393A KR20070017393A (ko) 2007-02-09
KR101371653B1 true KR101371653B1 (ko) 2014-03-07

Family

ID=34929150

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137002606A Ceased KR20130024969A (ko) 2004-05-28 2005-05-24 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린 유도체의 용도
KR1020067024974A Expired - Lifetime KR101371653B1 (ko) 2004-05-28 2005-05-24 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137002606A Ceased KR20130024969A (ko) 2004-05-28 2005-05-24 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린 유도체의 용도

Country Status (34)

Country Link
US (2) US20070249667A1 (enExample)
EP (1) EP1753427B1 (enExample)
JP (2) JP5081617B2 (enExample)
KR (2) KR20130024969A (enExample)
CN (2) CN1976704B (enExample)
AP (1) AP2037A (enExample)
AR (1) AR049127A1 (enExample)
AT (1) ATE390925T1 (enExample)
AU (1) AU2005249231B2 (enExample)
BR (1) BRPI0510414B1 (enExample)
CA (1) CA2566544C (enExample)
CL (1) CL2009001980A1 (enExample)
CY (1) CY1110388T1 (enExample)
DE (1) DE602005005810T2 (enExample)
DK (1) DK1753427T3 (enExample)
EA (1) EA010651B1 (enExample)
ES (1) ES2306146T3 (enExample)
HR (1) HRP20080307T3 (enExample)
IL (1) IL179630A (enExample)
JO (1) JO2524B1 (enExample)
ME (1) ME01105B (enExample)
MX (1) MXPA06013888A (enExample)
MY (1) MY140611A (enExample)
NO (1) NO338624B1 (enExample)
NZ (1) NZ550840A (enExample)
PA (1) PA8635201A1 (enExample)
PL (1) PL1753427T3 (enExample)
PT (1) PT1753427E (enExample)
RS (1) RS50585B (enExample)
SI (1) SI1753427T1 (enExample)
TW (1) TWI363625B (enExample)
UA (1) UA90267C2 (enExample)
WO (1) WO2005117875A1 (enExample)
ZA (1) ZA200609899B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306146T3 (es) * 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
HUE030264T2 (en) * 2005-06-28 2017-04-28 Janssen Pharmaceutica Nv Quinoline derivatives as antibacterial agents
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
WO2011031926A1 (en) * 2009-09-11 2011-03-17 Vertex Pharmaceuticals Incorporated Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-n-[3-(4-pyridyl)-1-[2-[4-pyridyl)ethyl]propanamide and uses thereof
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
EA035443B1 (ru) 2012-04-27 2020-06-17 Янссен Фармацевтика Нв Антибактериальные хинолиновые производные
DK2841426T3 (en) 2012-04-27 2017-01-09 Janssen Pharmaceutica Nv ANTIBACTERIAL QUINOLIN DERIVATIVES
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
HK1243644A1 (zh) * 2015-01-27 2018-07-20 Janssen Pharmaceutica Nv 可分散组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
KR102355154B1 (ko) * 2016-03-07 2022-01-26 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 항박테리아 화합물 및 그의 용도
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN111278985B (zh) * 2017-09-01 2023-09-08 学校法人北里研究所 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2021107876A1 (en) * 2019-11-26 2021-06-03 Nanyang Technological University Compounds for treating tuberculosis
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023227123A1 (zh) * 2022-05-27 2023-11-30 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CR20250175A (es) * 2022-11-15 2025-05-27 Lilly Co Eli Agonistas de ahr
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
EP0936866A4 (en) * 1996-10-28 2001-04-11 Dept Of The Army Us Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
ES2306146T3 (es) * 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. 12: 2501-2508 (2004.04.10.) *
Bioorg. Med. Chem. 12: 2501-2508 (2004.04.10.)*

Also Published As

Publication number Publication date
NZ550840A (en) 2010-01-29
CA2566544C (en) 2012-04-17
AP2037A (en) 2009-10-09
PT1753427E (pt) 2008-07-04
IL179630A (en) 2011-05-31
DE602005005810D1 (de) 2008-05-15
CY1110388T1 (el) 2015-04-29
JP5081617B2 (ja) 2012-11-28
IL179630A0 (en) 2007-07-04
US20070249667A1 (en) 2007-10-25
AP2006003828A0 (en) 2006-12-31
ATE390925T1 (de) 2008-04-15
JP2008500992A (ja) 2008-01-17
DE602005005810T2 (de) 2009-04-09
JP5675718B2 (ja) 2015-02-25
EA010651B1 (ru) 2008-10-30
AR049127A1 (es) 2006-06-28
HK1106136A1 (en) 2008-03-07
SI1753427T1 (sl) 2008-10-31
TW200608974A (en) 2006-03-16
EP1753427B1 (en) 2008-04-02
EA200602260A1 (ru) 2007-04-27
JO2524B1 (en) 2010-03-17
ME01105B (me) 2013-03-20
CA2566544A1 (en) 2005-12-15
US20100168133A1 (en) 2010-07-01
CN1976704A (zh) 2007-06-06
AU2005249231A1 (en) 2005-12-15
RS50585B (sr) 2010-05-07
WO2005117875A1 (en) 2005-12-15
HRP20080307T3 (hr) 2008-07-31
AU2005249231B2 (en) 2010-11-11
BRPI0510414B1 (pt) 2022-04-05
MY140611A (en) 2009-12-31
EP1753427A1 (en) 2007-02-21
CL2009001980A1 (es) 2010-04-16
MXPA06013888A (es) 2007-01-26
BRPI0510414A (pt) 2007-10-23
ZA200609899B (en) 2009-01-28
JP2012229239A (ja) 2012-11-22
CN1976704B (zh) 2012-12-05
PL1753427T3 (pl) 2008-09-30
NO338624B1 (no) 2016-09-19
NO20066041L (no) 2007-02-27
PA8635201A1 (es) 2006-05-16
CN102908347A (zh) 2013-02-06
UA90267C2 (ru) 2010-04-26
ES2306146T3 (es) 2008-11-01
DK1753427T3 (da) 2008-07-21
KR20130024969A (ko) 2013-03-08
TWI363625B (en) 2012-05-11
KR20070017393A (ko) 2007-02-09

Similar Documents

Publication Publication Date Title
KR101371653B1 (ko) 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도
KR100733577B1 (ko) 퀴놀린 유도체 및 마이코박테리아 저해제로서의 용도
de Souza Promising drugs against tuberculosis
KR101160183B1 (ko) 마이코박테리아 저해제로서 사용하기 위한 퀴놀린 유도체
JP2008500992A5 (enExample)
KR101150172B1 (ko) 치환된 퀴놀린 및 마이코박테리아 저해제로서의 용도
JP2025520237A (ja) ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
JP6426530B2 (ja) 潜伏性結核の処置
HK1106136B (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
HK1177427A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
de Souza Promising Drug Candidates in Advanced Clinical Trials
HK1186125A1 (en) Quinoline derivatives for the treatment of latent tuberculosis
HK1114006A (en) Quinoline derivatives for the treatment of latent tuberculosis
HK1186125B (en) Quinoline derivatives for the treatment of latent tuberculosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 21, Claim Number : 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 45, 46, 47, 49, 50, Period Limitation Text : 19, Comment Text : 42 5018

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 21, Claim Number : 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 45, 46, 47, 49, 50, Period Limitation Text : 19, Comment Text : 42 5018

FPAY Annual fee payment

Payment date: 20170220

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180219

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20200218

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250613

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION